Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study

Noriaki Iwao; Minoru Yoshida; Kiyohiko Hatake; Yoshiaki Hoshino; Shoutaro Hagiwara; Hiroshi Tomizuka; Ritsuko Shimizu; Toshiyuki Suzuki; Yusuke Furukawa; Norio Komatsu; Kazuo Muroi; Akiyoshi Miwa; Shinobu Sakamoto; Yasusada Miura

doi:10.1016/0145-2126(95)00072-0

Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study

Noriaki Iwao, Minoru Yoshida, Kiyohiko Hatake, Yoshiaki Hoshino, Shoutaro Hagiwara, Hiroshi Tomizuka, Ritsuko Shimizu, Toshiyuki Suzuki, Yusuke Furukawa, Norio Komatsu, Kazuo Muroi, Akiyoshi Miwa, Shinobu Sakamoto, Yasusada Miura

研究成果: Article › 査読

5 被引用数 (Scopus)

抄録

Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m²/day) and cytosine arabinoside (100 mg/m²/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.

本文言語	English
ページ（範囲）	899-903
ページ数	5
ジャーナル	Leukemia Research
巻	19
号	12
DOI	https://doi.org/10.1016/0145-2126(95)00072-0
出版ステータス	Published - 1995 12月
外部発表	はい

ASJC Scopus subject areas

血液学
腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/0145-2126(95)00072-0

他のファイルとリンク

引用スタイル

@article{a92bd41193f34e85af9f69f06dd85a65,

title = "Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study",

abstract = "Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.",

keywords = "Carboplatin, continuous infusion, cytosine arabinoside, high-risk leukemia, prolonged neutropenia",

author = "Noriaki Iwao and Minoru Yoshida and Kiyohiko Hatake and Yoshiaki Hoshino and Shoutaro Hagiwara and Hiroshi Tomizuka and Ritsuko Shimizu and Toshiyuki Suzuki and Yusuke Furukawa and Norio Komatsu and Kazuo Muroi and Akiyoshi Miwa and Shinobu Sakamoto and Yasusada Miura",

year = "1995",

month = dec,

doi = "10.1016/0145-2126(95)00072-0",

language = "English",

volume = "19",

pages = "899--903",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia

T2 - A pilot study

AU - Iwao, Noriaki

AU - Yoshida, Minoru

AU - Hatake, Kiyohiko

AU - Hoshino, Yoshiaki

AU - Hagiwara, Shoutaro

AU - Tomizuka, Hiroshi

AU - Shimizu, Ritsuko

AU - Suzuki, Toshiyuki

AU - Furukawa, Yusuke

AU - Komatsu, Norio

AU - Muroi, Kazuo

AU - Miwa, Akiyoshi

AU - Sakamoto, Shinobu

AU - Miura, Yasusada

PY - 1995/12

Y1 - 1995/12

N2 - Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.

AB - Fourteen patients with high-risk leukemia (six with relapsed AML, three with relapsed ALL, one with AML-M0, four with CML in myeloid blastic crisis) were treated with a combination chemotherapy of carboplatin (200-300 mg/m2/day) and cytosine arabinoside (100 mg/m2/day) by 24 h continuous infusion for 5-7 days. Five patients (35.7%) achieved complete remission including two patients complicated with myelofibrosis (one with AML-M0 and one with CML in myelo-megakaryocytic crisis). Thirteen patients had nausea and vomiting, five patients had severe, prolonged neutropenia for which it was necessary to administer granulocyte colony-stimulating factor and six patients had severe thrombocytopenia. We concluded that this regimen is effective for the treatment of high-risk leukemia.

KW - Carboplatin

KW - continuous infusion

KW - cytosine arabinoside

KW - high-risk leukemia

KW - prolonged neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0029618926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029618926&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(95)00072-0

DO - 10.1016/0145-2126(95)00072-0

M3 - Article

C2 - 8632658

AN - SCOPUS:0029618926

VL - 19

SP - 899

EP - 903

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -

Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル